– USA, MA – Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers, today announced the appointment of Scott Myers as Chairman of its Board of Directors.
About Scott Myers
Scott Myers served as President and CEO of Viridian in 2023, and before that, he was CEO of AMAG Technology, purchased by Covis Pharmaceuticals, SA in November of 2020. Before 2020, Scott Myers served as Chairman and CEO of Rainier Therapeutics, a private, clinical-stage biotechnology company focused on metastatic bladder cancer that was purchased by Fusion Pharmaceuticals in March of 2020. Before joining Rainier, Scott Myers served as CEO, President, and as director of Cascadian Therapeutics Inc. before its acquisition by Seattle Genetics in March of 2018. Mr. Myers also served as CEO of Aerocrine AB, a medical device company from 2011 to 2015 before its acquisition by Circassia.
Mr. Myers is serving as the Chairman of the Board of Dynavax Technologies, a commercial-stage vaccine company. Mr. Myers also serves as Chairman of the Board of Directors of Ironshore Pharmaceuticals, a private, commercial-stage ADHD company.
About Convergent Therapeutics, Inc.
Convergent Therapeutics Inc. is a clinical-stage biotechnology company focusing on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company’s proprietary technology was developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV01-α, a monoclonal antibody conjugated to actinium-225 (Ac-225), a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen. A key functional feature of CONV01-α is that once bound to PSMA, it becomes internalized, delivering its powerful radioactive payload directly into prostate cancer cells while minimizing damage to surrounding healthy tissue.
For more information: https://convergentrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.